JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wilke, R. A.
Right arrow Articles by Jackson, M. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wilke, R. A.
Right arrow Articles by Jackson, M. B.

Vol. 284, Issue 2, 542-548, February 1998

Dopamine D4 Receptor Mediated Inhibition of Potassium Current in Neurohypophysial Nerve Terminals1

Russell A. Wilke2 , Shyue-Fang Hsu and Meyer B. Jackson

Department of Internal Medicine, University of Wisconsin Hospital and Clinics, Madison, Wisconsin (R.A.W.), Department of Cardiology, Children's Hospital, Harvard Medical School, Boston, Massachusetts (S.-F.H.) and Department of Physiology, University of Wisconsin School of Medicine, Madison, Wisconsin (M.B.J.)

Dopamine influences the release of neurohypophysial peptides in vivo. However, the extent to which this effect is caused by a direct dopaminergic action within the neurohypophysis remains unclear. With use of the patch-clamp technique on thin slices of rat posterior pituitary glands, we now provide evidence that dopaminergic agonists inhibit potassium current (IK) in neurohypophysial nerve terminals. Superfusion with the dopamine receptor agonist, (±)-2-(N-phenylethyl-N-propyl)-amino-5-hydroxytetralin (PPHT), causes a reversible inhibition of whole-terminal IK under voltage clamp. This effect is concentration-dependent, with a maximal inhibition of 40 ± 5% and an EC50 of 1.8 ± 1.0 µM. It can be blocked with either a nonselective D2-like antagonist (100 µM eticlopride) or with the highly selective D4 antagonist, RBI-257 (10 µM). U101958 (a derivative of RBI-257) exhibits agonist activity similar to PPHT. Neither SKF 38393 (a D1/D5 agonist) nor quinpirole (a D2/D3 agonist) had any effect on whole-terminal IK in this preparation. Kinetic analysis demonstrated that the amplitude of both the rapidly and slowly inactivating phases of neurohypophysial IK are reduced by D4 receptor activation. These two separate current components have previously been shown to represent current through two distinct potassium channels, an A-current channel and a high-conductance Ca++-activated K+ channel. Thus, both channel types can be modulated by D4 receptors. This effect is likely to enhance the release of neurohypophysial peptides in vivo.

0022-3565/98/2842-0542$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
H.-W. Chang, V.-C. Wu, C.-Y. Huang, H.-Y. Huang, Y.-M. Chen, T.-S. Chu, K.-D. Wu, and B.-S. Hsieh
D4 dopamine receptor enhances angiotensin II-stimulated aldosterone secretion through PKC-{varepsilon} and calcium signaling
Am J Physiol Endocrinol Metab, March 1, 2008; 294(3): E622 - E629.
[Abstract] [Full Text] [PDF]

Home page
 Cereb CortexHome page
T. Demiralp, C. S. Herrmann, M. E. Erdal, T. Ergenoglu, Y. H. Keskin, M. Ergen, and H. Beydagi
DRD4 and DAT1 Polymorphisms Modulate Human Gamma Band Responses
Cereb Cortex, May 1, 2007; 17(5): 1007 - 1019.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
X. Wang, P. Zhong, and Z. Yan
Dopamine D4 Receptors Modulate GABAergic Signaling in Pyramidal Neurons of Prefrontal Cortex
J. Neurosci., November 1, 2002; 22(21): 9185 - 9193.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Interv.Home page
S. E. McKay and L. K. Kaczmarek
Act Locally: New Ways of Regulating Voltage-Gated Ion Channels
Mol. Interv., July 1, 2002; 2(4): 215 - 218.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
N. Hussy, V. Bres, M. Rochette, A. Duvoid, G. Alonso, G. Dayanithi, and F. C. Moos
Osmoregulation of Vasopressin Secretion via Activation of Neurohypophysial Nerve Terminals Glycine Receptors by Glial Taurine
J. Neurosci., September 15, 2001; 21(18): 7110 - 7116.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
P. J Lupardus, R. A Wilke, E. Aydar, C. P Palmer, Y. Chen, A. E Ruoho, and M. B Jackson
Membrane-delimited coupling between sigma receptors and K+ channels in rat neurohypophysial terminals requires neither G-protein nor ATP
J. Physiol., August 1, 2000; 526(3): 527 - 539.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. A. Wilke, R. P. Mehta, P. J. Lupardus, Y. Chen, A. E. Ruoho, and M. B. Jackson
Sigma Receptor Photolabeling and Sigma Receptor-mediated Modulation of Potassium Channels in Tumor Cells
J. Biol. Chem., June 25, 1999; 274(26): 18387 - 18392.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
R. A Wilke, P. J Lupardus, D. K Grandy, M. Rubinstein, M. J Low, and M. B Jackson
K+ channel modulation in rodent neurohypophysial nerve terminals by sigma receptors and not by dopamine receptors
J. Physiol., June 1, 1999; 517(2): 391 - 406.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.